Revolution Medicines' drug called Rasonque has been approved for marketing in the US. The drug can prolong the survival of patients with advanced pancreatic cancer. Rasonque is priced at over $475,000 per year and is one of the first drugs to broadly target RAS protein — a protein that is closely related to tumor growth and is mutated in most pancreatic cancers. The drug's approval has opened up a new front for a disease whose treatment is progressing slowly and where chemotherapy has been the core method for decades.

Revolution Medicines' drug called Rasonque has been approved for marketing in the US. The drug can prolong the survival of patients with advanced pancreatic cancer. Rasonque is priced at over $475,000 per year and is one of the first drugs to broadly target RAS protein — a protein that is closely related to tumor growth and is mutated in most pancreatic cancers. The drug's approval has opened up a new front for a disease whose treatment is progressing slowly and where chemotherapy has been the core method for decades.